Scroll to top

- Follow Us
- –
- Fb.
- Tw.
- Li.
- Yt.
- Inst.

SCENESSE^®
(afamelanotide 16mg)

US Residents

Visit www.scenesse.com

EU Package Leaflet

Download PDF

Published Research

CLINUVEL has conducted over 15 trials of SCENESSE^® (afamelanotide 16mg) involving over 900 patients, of which the published research can be purchased online.

Below is a selection of published research on SCENESSE^®. These links direct you to sites outside of the control of CLINUVEL and are not produced or endorsed by CLINUVEL.

Sancar, F. (2019). First Treatment for Rare Photosensitivity. Jama. 2019;322(19):1854-1854.

McNeil, M. M., Nahhas, A. F., Braunberger, T. L., Hamzavi, I. H. (2018). Afamelanotide in the Treatment of Dermatologic Disease. Skin Therapy Lett. 2018:23(6):6-10.

Minder, E. I., Barman-Aksoezen, J., Schneider-Yin, X. (2017). Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clinical pharmacokinetics, 2017;56(8):815-823.

See More

Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. Current and emerging treatments for vitiligo. Journal of the American Academy of Dermatology. 2017;77(1):17-29. doi:10.1016/j.jaad.2016.11.010

Langendonk J, Balwani M, Anderson K et al (2015). Afamelanotide for Erythropoietic Protoporphria. New England Journal of Medicine. 2015;373(1):48-59.

Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider‐Yin X, Minder E. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. British Journal of Dermatology. 2015;172(6):1601-1612.

Minder, E, Schneider-Yin, X. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology. 2015;8(1):43-53.

Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo: a randomized multicenter trial. JAMA Dermatology. 2015;151(1):42-50.

Biolcati G, Aurizi C, Barbieri L, Cialfi S, Screpanti I, Talora C. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey–Hailey disease. Clinical and experimental dermatology. 2014;39(2):168-175.

Bohm M, Ehrchen J, Luger TA. Beneficial effects of the melanocortin analogue Nle(4) -d-Phe(7) -α-MSH in acne vulgaris. Journal of the European Academy of Dermatology and Venereology. 2014;28(1):108-111.

Fabrikant J, Touloei K, Brown SM. “A Review and Update on Melanocyte Stimulating Hormone Therapy: Afamelanotide. Journal of drugs in dermatology: JDD. 2013;12(7):775.

Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes L. Systemic photoprotection in solar urticaria with α-melanocyte stimulating hormone analogue [Nle(4) -D-Phe(7) ]-α-MSH. British Journal of Dermatology. 2011;164(2):407-414.

Minder, EI. Afamelanotide melanocortin MC1 receptor agonist photoprotective agent. Drugs of the Future. 2010;35(5):365-372.

Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochemistry and photobiology. 2009;85(6):1434-1439.

Harms, J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. New England Journal of Medicine. 2009;360(3):306-307.

Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-α-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers. Journal of investigative dermatology. 2006;126(8):1869-1878.

Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.

Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN^®,[Nle4, D-Phe7]-α-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides. 2006;27(2):388-394.

Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 2000;72(4):526-532.

Levine N, Dorr R, Ertl G, Brooks C, Alberts D. Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: a dose-ranging study. Journal of dermatological treatment. 1999;10(2):127-132.

Over 200 articles have been published on afamelanotide (chemical name [Nle4, D-Phe7]α-MSH or NDP-MSH).

CONTACT

Questions ?

Get in touch